Published by
The Street
The Street
By PR Newswire SEOUL, South Korea, Jan. 4, 2022 /PRNewswire/ — BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy. Under the collaboration agreement, BIORCHESTRA, a South Korea-based privately-held biotech company that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology. BIORCHESTRA has a platform using antisense oligonucleotides [2] (AS…